\[Purpose of the Clinical Study\]:The purpose of this study is to conduct a clinical comparison of low-dose rosuvastatin plus ezetimibe combination therapy and high-dose rosuvastatin monotherapy in patients with minimal to intermediate coronary artery disease without percutaneous coronary intervention to confirm non-inferiority in the reduction of key cardiovascular events.
\[Hypothesis\]:In patients who have not undergone percutaneous coronary intervention for minimal to moderate coronary artery disease, low-dose rosuvastatin and ezetimibe combination therapy are non-inferior in terms of reducing major cardiovascular events compared to high-dose rosuvastatin monotherapy.
Male and female adjusts (19 or older)
Patients with suspected stable angina pectoris without coronary artery interventions, who showed a minimal to intermediate coronary artery diseases (a stenosis of 10 to 70% diameter as per QCA) in at least one natural coronary artery in coronary artery angiography or coronary artery CT.
Patients who gave their informed consent themselves in writing.
Patients who were treated with statin or lipid-lowering agents may participate in the study by changing the existing medicines.
Patients with an intermediate (>30%) lesion on the left main coronary artery.
Patients diagnosed with acute coronary artery diseases (STEMI, NSTEMI, Unstable angina)
Patients who received percutaneous coronary intervention
Patients who have been diagnosed with stroke, transitory ischemic attack, and peripheral artery diseases.
Parallel
Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
DrugOral administration once a day, taking it for 3 years
Mono drug group of Rosuvastatin 20 mg
DrugOral administration once a day, taking it for 3 years
The occurrence rates of the compound variables
The occurrence rates of the compound variables of all cause deaths, cardiac deaths, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to unstable angina, and revascularization after taking the study medicine at the time of Visit 5 (36 month) were compared between groups
Click on the lead sponsor to view all of their trials.
